PMID- 24767731
OWN - NLM
STAT- MEDLINE
DCOM- 20140909
LR  - 20171116
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 71
IP  - 1
DP  - 2014 Jul
TI  - Ipilimumab in patients with cancer and the management of dermatologic adverse 
      events.
PG  - 161-9
LID - S0190-9622(14)01152-9 [pii]
LID - 10.1016/j.jaad.2014.02.035 [doi]
AB  - Ipilimumab is a fully human monoclonal antibody that blocks cytotoxic 
      T-lymphocyte antigen-4 to augment antitumor T-cell responses. Phase III studies 
      have demonstrated survival benefit in both previously treated and treatment-naive 
      patients with metastatic melanoma. In clinical trials, adverse events (AEs) 
      related to treatment with ipilimumab were mostly grade 1/2 (as per Common 
      Terminology Criteria for AEs, Version 4.02), and mostly reversible with 
      appropriate management. Distinct immune-related AEs that may reflect the 
      mechanism of action of ipilimumab have been identified, and occur commonly in the 
      skin, typically presenting as a maculopapular rash, which can be accompanied by 
      pruritus, pruritus with no skin lesions, alopecia, and vitiligo. Histologic 
      analyses have revealed epidermal spongiosis, and perivascular CD4(+) T-cell 
      infiltrates with some eosinophils in areas of rash. Timely implementation of 
      toxicity-specific treatment guidelines that emphasize vigilance and early 
      intervention allows mitigation of dermatologic AEs. Adherence to guidelines is 
      necessary to maintain quality of life, ensure consistent dosing, and obtain the 
      best possible clinical outcome.
CI  - Copyright (c) 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. 
      All rights reserved.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Memorial Sloan Kettering Cancer Center, New York, New York; Weill-Cornell Medical 
      College, New York, New York. Electronic address: lacoutum@mskcc.org.
FAU - Wolchok, Jedd D
AU  - Wolchok JD
AD  - Memorial Sloan Kettering Cancer Center, New York, New York; Weill-Cornell Medical 
      College, New York, New York; Ludwig Institute for Cancer Research, New York, New 
      York.
FAU - Yosipovitch, Gil
AU  - Yosipovitch G
AD  - Departments of Dermatology, Neurobiology and Anatomy, and Regenerative Medicine, 
      Wake Forest University Health Sciences, Winston-Salem, North Carolina.
FAU - Kahler, Katharina C
AU  - Kahler KC
AD  - Department of Dermatology, University of Kiel, Kiel, Germany.
FAU - Busam, Klaus J
AU  - Busam KJ
AD  - Memorial Sloan Kettering Cancer Center, New York, New York.
FAU - Hauschild, Axel
AU  - Hauschild A
AD  - Department of Dermatology, University of Kiel, Kiel, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140424
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Alopecia/chemically induced
MH  - Antibodies, Monoclonal/*adverse effects/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects/pharmacology/*therapeutic use
MH  - Exanthema/chemically induced/therapy
MH  - Humans
MH  - Hypopigmentation/chemically induced
MH  - Ipilimumab
MH  - Melanoma/*drug therapy
MH  - Pruritus/chemically induced
MH  - Skin Neoplasms/*drug therapy
MH  - T-Lymphocytes/drug effects
OTO - NOTNLM
OT  - adverse event management
OT  - dermatologic
OT  - immune-related
OT  - ipilimumab
OT  - melanoma
OT  - pruritus
OT  - rash
OT  - vitiligo
EDAT- 2014/04/29 06:00
MHDA- 2014/09/10 06:00
CRDT- 2014/04/29 06:00
PHST- 2013/10/01 00:00 [received]
PHST- 2014/02/20 00:00 [revised]
PHST- 2014/02/24 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
AID - S0190-9622(14)01152-9 [pii]
AID - 10.1016/j.jaad.2014.02.035 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2014 Jul;71(1):161-9. doi: 10.1016/j.jaad.2014.02.035. Epub 
      2014 Apr 24.